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Less blood means more sanguinity
Angiostatin, a recently discovered anti-angiogenic factor, offers the
hope of long-term control of metastatic cancers following surgery.
The progression of a tumour from the benign to the
malignant depends upon the acquisition of multiple
genetic mutations within the cancer cells [1]. But one
aspect that is common to the success of nearly every
tumour's growth and dissemination is the absolute
requirement of the expanding tumour to nourish itself.
This is achieved by the promotion of angiogenesis, in
which the growth of new capillaries is stimulated by
means of the proliferation of endothelial cells within the
tumour mass [2]. As well as providing the tumour with
nutrients and oxygenation, the angiogenic competence
of most primary tumours has the potentially lethal conse-
quence of providing multiple access points through
which metastatic tumour cells can reach the circulation.
Angiogenesis is, therefore, an attractive target for thera-
peutic intervention, not least because it is not highly
dependent upon cancer type or location.
Experimental models have shown that a solid tumour
cannot grow larger than 1-2 mm in diameter without
the induction of significant angiogenesis to supply its
metabolic needs. In addition, recent studies have identi-
fied a range of angiogenic factors that are produced
either by the tumour cells themselves or by tumour-asso-
ciated cells, such as the surrounding fibroblasts or
macrophages [2]. The relevance of such studies to clinical
practice has been confirmed by the demonstration of a
strong correlation between the number of microvessels
detectable at the advancing front of the primary tumour
and the incidence of metastatic disease in women with
breast cancer [3].
Several much more poorly characterized observations,
however, suggest that tumours do not have things all
their own way [1]. In particular, the presence of a pri-
mary tumour can sometimes inhibit the growth of its
own metastases at distant sites, a phenomenon known as
inhibition of (distant) tumour growth by tumour mass
(Fig. 1) [4]. Thus, the metastases of some human cancers
seem to proliferate much more rapidly following surgi-
cal removal of all or part of the primary tumour [5]. In
addition, in certain animal models of cancer, a resistance
to challenge with a secondary tumour can develop in
animals that already bear a primary tumour, an effect that
is dependent on the size of the primary tumour [4]. To
explain such observations, imprecisely defined mecha-
nisms have been proposed, in which the primary tumour
either indirectly induces a vaccinating immunity to sub-
sequent challenge (so-called concomitant immunity) [6],
or directly releases into the circulation unidentified anti-
mitotic factors which restrain growth of the secondary
metastases (Fig. 1) [7]. Now, however, O'Reilly and col-
leagues from Judah Folkman's laboratory [8] have pro-
vided a molecular explanation by identifying a diffusible
factor, released from a primary mouse tumour, which
exerts a potent suppressive effect on the growth of
metastases in the lungs.
The Boston group screened several murine tumour cell
lines in a search for one in which the primary tumour
that develops from the line inhibits the growth (but not
the number) of its own metastases in the lungs. Of the
cell lines screened, the 3LL Lewis lung carcinoma line,
LLC-LM, was the most effective. LLC-LM lung metas-
tases became highly neovascularized only after removal of
the experimentally introduced primary subcutaneous
tumour, and the cells within the metastases then showed
a significant reduction in the level of apoptotic cell death
compared to that in metastases growing in the presence
of a primary tumour (Fig. 2a). Having shown that the
primary tumour can exert long-range growth control
over secondary tumours, the activity responsible was
identified as a circulating factor in the serum of primary
tumour-bearing animals; it could both inhibit experi-
mental vascularization and reduce the proliferation in
vitro of several endothelial cell lines, but not of a range of
tumour cells (Fig. 2b).
The active component, purified from the serum as a
38 kD protein, was shown to be virtually identical to
a 342 amino-acid internal fragment of plasminogen, a
protease involved in the blood-clotting cascade. A simi-
lar fragment of human plasminogen strongly inhibited
proliferation of endothelial cells in vitro, and could
Fig. 1. Competing influences affect the development of metastases.
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Molecular and biochemical characterization of angio-
statin finally provides the framework for a credible work-
ing hypothesis to explain the inhibition of (distant)
tumour growth by tumour mass. Angiostatin has a rela-
tively long half-life in the mouse circulation (tA around
2.5 days), as compared to the brief existence of vascular
endothelial growth factor (VEGF), the principal angio-
genic potentiator of the 3LL tumour model. An estab-
lished primary tumour that releases high levels of VEGF
will, therefore, promote angiogenesis in its own vascular
bed, but the levels of VEGF will fall off rapidly at dis-
tances away from the tumour. Conversely, even tumours
that release only low levels of angiostatin locally will
cause the build up of relatively high serum levels of the
protein over time, inhibiting neovascularization of distant
metastatic capillary beds. Removal of the primary
tumour will remove the largest chronic source of angio-
genic inhibitors so that, with time, angiogenesis will
reappear in a metastasis as the balance of local stimulators
(VEGF) and serum-borne inhibitors (angiostatin) swings
in favour of metastatic growth.
If angiostatin is found to have a similar disease-control-
ling role in humans to that in the 3LL mouse model, it
may help to provide both prognostic information and
may even help directly in patient management (Fig. 3).
The most life-threatening aspect of cancer is usually the
development of metastases in vital organs. Often, a clini-
cian will suspect the presence of occult metastases at the
time of surgery but is powerless to prevent their develop-
ment into lethal tumours. Surgery remains the best treat-
ment option for most patients, to prevent the shedding of
more metatstatically competent tumour cells into the cir-
culation and, in some cases, early surgery will be curative
(Fig. 4a). Unfortunately, in the later stages of disease pro-
gression, the loss of the primary tumour might actually
pose a real threat by causing the release of growth
restraints on metastatic growth (Fig. 4).
The justification for surgery cannot be doubted - the
risk of metastasis is, after all, directly proportional to the
number of cells that enter the circulation [9]. But effec-
tive anti-metastatic adjuvant therapy at the time of, and
Fig. 2. Identification and purification of angiostatin.
suppress the growth of 3LL lung metastases with an
efficiency at least as high as that of a primary tumour
(Fig. 2c). Only the active fragment of plasminogen, and
not the entire protein, was capable of reproducing the
anti-metastatic activity. The authors [8] named the pro-
tein angiostatin, and confirmed that it is present in the
serum of mice bearing primary 3LL tumours, and that its
potent anti-angiogenic activity correlates well with the
anti-proliferative activity of primary 3LL tumours on
distant metastases. Fig. 3. Theoretical uses of angiostatin.
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to other types of therapies [10], such as chemotherapy,
radiotherapy, or even gene therapy, the beneficial effects
of which would otherwise be swamped by the rapid
development of metastatic growth following surgery.
The discovery of angiostatin may also help to explain
another conundrum of cancer therapy, in which some
patients - following apparently successful surgery - can
suddenly develop aggressive, lethal recurrence of metasta-
tic growths after periods of many years that are seemingly
disease free. Why the tumour cells remain dormant for so
long, and why they escape clearance, has not been satis-
factorily explained. Perhaps the release of factor(s) such as
angiostatin, initially by the primary tumour and then later
by multiple micro-metastases, establishes sufficiently high
systemic levels of anti-angiogenic factors to control
metastatic growth over periods of years. Only when some
perturbation of the system alters that fine balance can the
secondary tumours expand, as a result of their now
increased angiogenic potential. Screening patients who
are currently in remission for alterations in levels of fac-
tors such as angiostatin may therefore provide clues as to
the short-term course of latent disease. This information
may help to predict imminent relapse and may provide
cues for the prompt instigation of protective treatments
aimed at controlling subsequent recurrences (Fig. 4c).
The identification of angiostatin also adds one more
member to the ever-growing list of potential tumour-sup-
pressor (or, more accurately, metastasis-suppressor) pro-
teins. Loss of function of the angiostatin gene may
therefore be associated with a more aggressive progression
of disease, and it may become possible to develop genetic
screens that assess the integrity of the angiostatin gene in
order to predict the likely severity of disease (Fig. 3),
although this possibility remains very speculative until
much more work has been done with human patients.
Fig. 4. The proposed role of angiostatin in the development of
metastases from primary tumours.
following, surgery might enhance patient survival in
these particular cases (Fig. 4), and this is where the ex-
periments reported in the recent Cell paper [8] assume
such potential significance for cancer treatment. If human
angiostatin is found to be active against the growth of
human metastases, long-term control of microscopic dis-
ease may be possible. The purification of therapeutic
amounts of angiostatin may allow the benefits of surgery
to be preserved, while the simultaneous administration of
a metastasis-inhibiting drug would compensate for any
adverse effects of the loss of the primary tumour (Fig.
4d). Although such a treatment regimen is unlikely to
cure the metastases, it may make control a realistic
option. In this way, a tactical advantage may be afforded
Not surprisingly, several questions remain unanswered,
and it is important to maintain a realistic perspective on
the significance of the discovery of angiostatin,
particularly as it relates to the future therapy of human
disease. For example, angiostatin is a new protein, the
normal function of which has yet to be explained. As it is
an internal fragment of plasminogen, it is possible that
angiostatin is merely a fortuitous by-product of natural
proteolytic cleavage reactions in vivo and that, of itself, it
has no function beyond the particular experimental sys-
tem in which it has been identified. Alternatively, the
angiostatin fragment of plasminogen may have evolved
for genuine physiological reasons. These might include
providing a natural defence against cancer development,
and/or a function in normal processes - such as termi-
nation of wound healing - in which a burst of
angiogenesis must be terminated. The origins of the cir-
culating angiostatin in tumour-bearing mice also remains
a mystery. Many proteases are known to be released near
invasive cancers, both by the tumour cells and by nearby
activated fibroblasts, and these might be responsible for
cleaving plasminogen into the active angiostatin species.
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Alternatively, the tumour cells themselves may secrete
plasminogen, or even angiostatin, directly.
As yet, angiostatin has been demonstrated to be effective
in only one murine model system. Whether the mol-
ecule has any efficacy against, for example, human cell
lines growing in athymic mice, let alone in patients, has
yet to be shown. Excessive optimism based on control of
experimental cancers in mice is a dangerous luxury. As a
result of their extreme genetic plasticity, human tumour
cells have a long and distinguished track record of eva-
ding promising therapeutic strategies. Indeed, repeated
passage in mice of the 3LL tumour cells used to identify
angiostatin eventually generated a variant in which
growth of the primary tumour no longer protected
against development of distant metastases [8]; the emer-
gence of human tumours that can evade any single anti-
angiogenic therapy is likely to be as swift within a
patient. In addition, Folkman and colleagues [8] showed
that other types of primary tumour are less effective in
protecting the host from growth of metastases than Lewis
lung carcinomas, so it seems likely that not all (if any)
human cancers will be responsive to angiostatin-based
therapies. Finally, a range of promising anti-angiogenic
compounds are already in clinical trials [11], and the
results of these trials will give an indication of the efficacy
of targeting tumour angiogenesis as a therapeutic strategy.
Despite these reservations, the prospect of a drug that
confers long-term control over metastatic growth in situ
is extremely appealing. The very near future should see
answers to many of the questions that many cancer clini-
cians, constantly frustrated by an inability to control the
insidious progression of metastatic lesions, will be asking
about angiostatin. Screening patients for circulating levels
of the molecule in vivo, demonstration of.its activity
against angiogenesis in human tumours, and correlation
with the course of human disease are no doubt well
underway by now. The hope is that angiostatin will be
able to make the transition from animal model to human
patient with more success than many of its predecessors.
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